Related Experiment Video
Updated: Mar 26, 2026
New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place
1University of Michigan Health System, Ann Arbor, MI, USA University of Michigan, College of Pharmacy, Ann Arbor, MI, USA nghih@med.umich.edu.
Insights
Patients with cirrhosis face increased risks of bleeding and thrombosis. Low-molecular-weight heparin (LMWH) is recommended for anticoagulation, with close monitoring for complications.
Area of Science:
- Hepatology
- Hematology
- Pharmacology
Background:
- Cirrhosis significantly alters the coagulation cascade, impacting both procoagulant and anticoagulant factors.
- This complex hemostatic imbalance increases the risk of both bleeding and thrombotic events in cirrhotic patients.
- Understanding these changes is crucial for effective anticoagulation management.
Purpose of the Study:
- To review current literature on anticoagulation strategies in patients with cirrhosis.
- To summarize the effects of cirrhosis on coagulation.
- To outline recommendations for monitoring and treatment.
Main Methods:
- Systematic electronic literature search in PubMed (2000-2015).
- Inclusion of English-language studies focusing on anticoagulation, cirrhosis, and related thrombotic/bleeding events.
- Independent review of search results for relevance.
Main Results:
- Cirrhosis leads to elevated international normalized ratio (INR) and activated partial thromboplastin time (aPTT), with decreased anti-factor Xa (anti-Xa) levels.
- Low-molecular-weight heparin (LMWH) is identified as the preferred agent for deep-vein thrombosis (DVT), pulmonary embolism (PE), and portal vein thrombosis (PVT) prevention and treatment.
- Monitoring anti-Xa levels for LMWH dose adjustment in cirrhosis is not recommended.
Conclusions:
- Cirrhotic patients require careful anticoagulation management due to dual risks of bleeding and thrombosis.
- LMWH is the recommended anticoagulant, while unfractionated heparin (UFH) serves as an alternative in specific clinical scenarios.
- Close clinical monitoring for bleeding and thrombosis is essential for cirrhotic patients on anticoagulation therapy.
Objective:
To review current literature for anticoagulation in patients with cirrhosis and provide a summary of the effects of cirrhosis on the coagulation cascade, therapeutic monitoring through interpretation of antifactor Xa (anti-Xa), activated partial thromboplastin time (aPTT), and international normalized ratio (INR) as well as current prophylaxis and treatment recommendations in cirrhotic patients.
Methods:
A systematic electronic literature search was conducted in PubMed using the key termsanticoagulation, warfarin, low-molecular-weight heparin(LMWH),unfractionated heparin(UFH),target-specific oral anticoagulants, deep-vein thrombosis(DVT),pulmonary embolism(PE),portal vein thrombosis(PVT),venous thromboembolism, anti-Xa, activated partial thromboplastin time, anticoagulation therapeutic monitoring, coagulopathy, coagulation cascade, chronic liver disease, cirrhosis, anddecompensated liver disease
Study Selection:
Studies written in the English language from January 2000 to December 2015 were considered for this review article. All search results were reviewed, and the relevance of each article was determined by authors independently.
Conclusions:
Patients with cirrhosis are at higher risk for both bleeding and thrombosis-related complications. Cirrhosis affects production of both procoagulant and anticoagulant factors, thus resulting in increased INR and aPTT levels and decreased anti-Xa levels. LMWH is the treatment of choice for the prevention and treatment of DVT/PE/PVT in patients with cirrhosis, and monitoring with anti-Xa levels for dose adjustment is not recommended. UFH is an alternative in cirrhotic patients for shorter-term use and in cases of severe renal dysfunction and/or hemodynamic instability. Cirrhotic patients on anticoagulation therapy should be monitored closely for signs and symptoms of bleeding and thrombosis.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Venous Thrombosis IV: Nursing Management
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow